{"id":"agb101","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Injection site reactions"},{"rate":"10-20%","effect":"Headache"},{"rate":"5-10%","effect":"Fatigue"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"AGB101 works by binding to amyloid-beta, a protein associated with Alzheimer's disease, to prevent its aggregation and clearance. This mechanism is thought to reduce the burden of amyloid-beta in the brain, potentially slowing disease progression.","oneSentence":"AGB101 is a monoclonal antibody targeting amyloid-beta","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T02:21:17.938Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Alzheimer's disease"}]},"trialDetails":[{"nctId":"NCT05824728","phase":"PHASE2","title":"Clinical Trial Evaluating the Efficacy and Safety of AGB101 for Treatment of Parkinson's Disease Related Psychosis","status":"RECRUITING","sponsor":"Johns Hopkins University","startDate":"2023-09-28","conditions":"Parkinson Disease Psychosis","enrollment":30},{"nctId":"NCT05986721","phase":"PHASE2","title":"Clinical Trial of AGB101 for Mild Cognitive Impairment","status":"WITHDRAWN","sponsor":"AgeneBio","startDate":"2024-12-03","conditions":"Mild Cognitive Impairment, Prodromal Alzheimer's Disease","enrollment":""},{"nctId":"NCT06919926","phase":"PHASE2","title":"Clinical Trial Evaluating the Efficacy of AGB101 for Reducing Hippocampal Overactivity in Older Adults","status":"RECRUITING","sponsor":"Johns Hopkins University","startDate":"2025-04-17","conditions":"Hippocampal Overactivity, Dementia","enrollment":60},{"nctId":"NCT03486938","phase":"PHASE2, PHASE3","title":"Study of AGB101 in Mild Cognitive Impairment Due to Alzheimer's Disease","status":"COMPLETED","sponsor":"AgeneBio","startDate":"2018-12-13","conditions":"Mild Cognitive Impairment, Prodromal Alzheimer's Disease","enrollment":164},{"nctId":"NCT03461861","phase":"PHASE2","title":"Network-Level Mechanisms for Preclinical Alzheimer's Disease Development","status":"COMPLETED","sponsor":"Medical College of Wisconsin","startDate":"2019-04-11","conditions":"APOE 4","enrollment":26}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":3,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["levetiracetam","keppra"],"phase":"phase_2","status":"active","brandName":"AGB101","genericName":"AGB101","companyName":"AgeneBio","companyId":"agenebio","modality":"Small molecule","firstApprovalDate":"","aiSummary":"AGB101 is a monoclonal antibody targeting amyloid-beta Used for Alzheimer's disease.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}